Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial

Gastaminza, Gabriel; Azofra, Julián; Núñez‐Córdoba, Jorge M.; Baeza, M.L.; Echechipía, S.; Gaig, P.; García, Blanca E.; Labrador‐Horrillo, Moisés; Sala‐Cunill, Anna; Sabaté‐Brescó, Marina; Beristain, Ana; Quiñones, Dolores; Donado, Carmen Díaz; Zubeldía, J M; Ferrer, Marta

doi:10.1016/j.jaip.2018.12.025

Cited by 43 publications

(30 citation statements)

References 40 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cold urticaria patients for example are assessed for their individual critical temperature thresholds, i.e., the warmest temperature that is cold enough to produce a wheal, with the help of the Temptest [80]. Trigger threshold measurements for determining disease activity in patients with CIndU can be complemented by the use of CIndU-specific disease activity scores, such as the Cholinergic Urticaria Activity Score [81], that should be validated. Disease activity scores for CIndUs take into account the actual daily exposure of patients to relevant triggers.…”

Section: What Tools Should Be Used To Assess Disease Activity and Conmentioning

confidence: 99%

Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

Maurer

Eyerich

et al. 2020

Int Arch Allergy Immunol

Self Cite

141

View full text Add to dashboard Cite

show abstract

Section: What Tools Should Be Used To Assess Disease Activity and Conmentioning

confidence: 99%

Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

Maurer

Eyerich

et al. 2020

Int Arch Allergy Immunol

Self Cite

141

View full text Add to dashboard Cite

show abstract

“…In non-responders, it is recommended to increase the dose of nsAH up to 4-fold or use add-on therapy with omalizumab (anti-IgE) if no effect is seen with updosed nsAH. 5 Several clinical studies have established the effectiveness and safety of omalizumab in CSU 6-9 and a few studies have also described successful treatment with omalizumab in patients with CholU, 4,10 however, larger real-life studies on effectiveness, safety and adherence to omalizumab in CholU patients are lacking.…”

mentioning

confidence: 99%

Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature

Ghazanfar

Holm

Thomsen

2020

Dermatologic Therapy

View full text Add to dashboard Cite

To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63.9%) were refractory to updosed non-sedating antihistamines and initiated omalizumab in the observation period. Among these, an improvement of 10.8 UAS7 points (4.6-17.0), P = .002, was seen at 6 months follow up. DLQI and disease bother score VAS also improved significantly from before initiating treatment with omalizumab to follow-up; 7.0 points (3.6-10.3), P < .001 and 3.1 points (1.5-4.8), P = .001, respectively. The overall mean drug survival time for omalizumab (discontinued due to any cause) was 30.6 months (22.2-39.0). A total of five patients (21.7%) reported suspected side effects (headache, muscle pain, fatigue and injection site reactions) during treatment with omalizumab until 6 months follow-up. The systematic literature review identified 58 additional antihistamine refractory patients with CholU treated with omalizumab. The available studies reported that omalizumab is effective in patients with CholU and improves their disease-related quality of life. Omalizumab is safe, reduces disease activity and improves disease-related quality of life in patients with CholU.

show abstract

“…In a randomized clinical trial involving 22 CholU patients, the negative rate of exercise challenge test was 31.3% at week 48, and daily symptoms score and VAS score progressively improved week 16 after treatment with 300 mg omalizumab. 6 Our study showed that 19 (70.4%) of 27 CholU patients and 13 (61.9%) of 21 patients with CholU were partial or complete responders, providing indirect evidence for the good efficacy of omalizumab for H 1 AH-refractory CholU in an Asian country. Moreover, of 8 non-responders, 6 received only 150 mg omalizumab without up-dosing, and 5 received omalizumab only for 2 months.…”

mentioning

confidence: 53%